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Abstract
Background: Although the c.904_906delGAG mutation in Exon 5 of TOR1A typically manifests as
early-onset generalized dystonia, DYT1 dystonia is genetically and clinically heterogeneous.
Recently, another Exon 5 mutation (c.863G>A) has been associated with early-onset generalized
dystonia and some ΔGAG mutation carriers present with late-onset focal dystonia. The aim of this
study was to identify TOR1A Exon 5 mutations in a large cohort of subjects with mainly non-
generalized primary dystonia.
Methods: High resolution melting (HRM) was used to examine the entire TOR1A Exon 5 coding
sequence in 1014 subjects with primary dystonia (422 spasmodic dysphonia, 285 cervical dystonia,
67 blepharospasm, 41 writer's cramp, 16 oromandibular dystonia, 38 other primary focal dystonia,
112 segmental dystonia, 16 multifocal dystonia, and 17 generalized dystonia) and 250 controls (150
neurologically normal and 100 with other movement disorders). Diagnostic sensitivity and
specificity were evaluated in an additional 8 subjects with known ΔGAG DYT1 dystonia and 88
subjects with ΔGAG-negative dystonia.
Results: HRM of TOR1A Exon 5 showed high (100%) diagnostic sensitivity and specificity. HRM
was rapid and economical. HRM reliably differentiated the TOR1A ΔGAG and c.863G>A mutations.
Melting curves were normal in 250/250 controls and 1012/1014 subjects with primary dystonia.
The two subjects with shifted melting curves were found to harbor the classic ΔGAG deletion: 1)
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a non-Jewish Caucasian female with childhood-onset multifocal dystonia and 2) an Ashkenazi Jewish
female with adolescent-onset spasmodic dysphonia.
Conclusion: First, HRM is an inexpensive, diagnostically sensitive and specific, high-throughput
method for mutation discovery. Second, Exon 5 mutations in TOR1A are rarely associated with
non-generalized primary dystonia.
Background
Dystonia is a syndrome of sustained muscle contractions,
frequently causing twisting and repetitive movements, or
abnormal postures [1]. Dystonia can be classified by etiol-
ogy (primary or secondary), age of onset (childhood-
onset [0–12 yrs], adolescent-onset [13–20 yrs], or late-
onset [>20 yrs]), and anatomical distribution (focal, seg-
mental, multifocal, hemidystonia, or generalized) [1-4].
Primary generalized dystonias usually begin in childhood
or adolescence, whereas focal dystonias typically present
during adult life. Primary dystonia includes syndromes in
which dystonia is the sole phenotypic manifestation, with
the exception that tremor may be present as well.
In most neurology subspecialty practices, the vast major-
ity of patients with dystonia are adults with primary focal
or segmental disease. Genetic factors likely play a major
role in late-onset primary dystonia since 8–27% of
patients with primary late-onset dystonia have one or
more family members affected with dystonia [5-9] and
several of the primary dystonias inherited in Mendelian
fashion (DYT1, DYT5, DYT6, DYT11, and DYT12) begin
focally, show incomplete penetrance and exhibit variable
anatomical expressivity [10-12]. These facts suggest that
sporadic late-onset dystonia, much like Parkinson's dis-
ease, is a complex disorder with contributions from mul-
tiple genes and environmental factors. Candidate gene
studies have been successful in several late-onset neuro-
logical disorders, particularly Parkinson's disease, and
may be fruitful in primary dystonia. Late-onset sporadic
dystonia could be associated with a number of distinct
mutations of low penetrance.
The  ΔGAG (c.904_906delGAG) mutation in Exon 5 of
TOR1A is characteristically associated with early-onset gen-
eralized dystonia [13]. Although infrequent, the DYT1
ΔGAG mutation has also been associated with late-onset
focal, segmental, and multifocal dystonia [14-19]. Another
mutation in Exon 5 of TOR1A  (c.863G>A) has been
described in a female patient with severe childhood-onset
generalized dystonia [20]. The G>A transition in Exon 5
results in exchange of an arginine for glutamine. In contrast
to the DYT1 ΔGAG mutation, analysis of late-onset dysto-
nia cases for the c.863G>A mutation has not been
described to date. Two additional mutations have been
described in Exon 5, the terminal exon of TOR1A. Leung
and colleagues [21] reported a patient with early-onset dys-
tonia and myoclonus who harbored an 18-bp deletion in
Exon 5 which should eliminate 6 amino acids near the car-
boxy terminus of torsinA (Phe323_Tyr328del), including a
putative phosphorylation site. The causality of the 18-bp
deletion is unclear since the same subject was subsequently
found to have an SGCE mutation [22]. As described in
another study, a novel out-of-frame 4-bp deletion
(c.934_937delAGAG) found in a putatively healthy blood
donor should result in an alteration of amino acids starting
at position 312 with a premature stop at position 325
(E312/Stop325) in the carboxy terminus of torsinA [18].
To help address the role of the TOR1A gene in non-gener-
alized primary dystonia, we used high resolution melting
(HRM) to examine the entire TOR1A  Exon 5 coding
sequence in a large cohort of patients with non-general-
ized dystonia. HRM has been shown to be a fast and accu-
rate, closed-tube, post-PCR mutation scanning technique
that monitors the progressive change in fluorescence
caused by the release of an intercalating DNA dye from
DNA duplexes as they are denatured by minor increases in
temperature [23]. Our results indicate that mutations in
Exon 5 of TOR1A are rare in non-generalized primary dys-
tonia.
Methods
Subjects
All human studies were performed in accordance with
institutional review board guidelines and all subjects gave
informed consent. Subjects with dystonia and neurologi-
cally-normal controls were acquired from outpatient clin-
ics at participating institutions (University of Tennessee
Health Science Center, Bastian Voice Institute, Washing-
ton University School of Medicine in St. Louis, New York
Center for Voice and Swallowing Disorders, Mayo Clinic
Jacksonville, Beth Israel Deaconess Medical Center, Van-
derbilt University and the Parkinson's & Movement Disor-
der Institute) and support group meetings of the National
Spasmodic Dysphonia Association (NSDA), National
Spasmodic Torticollis Association (NSTA), Benign Essen-
tial Blepharospasm Research Foundation (BEBRF), Dysto-
nia/Spasmodic Torticollis, and Dystonia Medical
Research Foundation (DMRF). All subjects with dystonia
acquired at support group meetings were examined by
M.S.L. Subjects with Parkinson's disease and other move-
ment disorders were acquired from the clinics of M.S.L.
and R.F.P. Clinical diagnoses and classifications wereBMC Medical Genetics 2009, 10:24 http://www.biomedcentral.com/1471-2350/10/24
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made by means of history and examination by one or
more neurologists and/or neurolaryngologist at each
institution. Neurologically-normal control subjects were
defined as individuals with no personal or first-degree
family history of neurological disease. In addition, all
control subjects acquired at the University of Tennessee
Health Science Center and support group meetings were
examined by M.S.L. or R.F.P. Dystonia was classified in
accordance with established schemes [1,3,24]. Subjects
with established diagnoses of DYT1 dystonia were not
recruited into our study.
Clinical diagnoses for 1264 subjects interrogated with
HRM appear in Table 1. Demographic information and
dystonia distribution was not available for 96 DNA sam-
ples received from Athena Diagnostics, Inc. (Worcester,
MA). The panel from Athena Diagnostics included 8 sam-
ples with confirmed DYT1 ΔGAG deletions and 88 ΔGAG-
negative samples associated with a clinical diagnosis of
"dystonia."
DNA
DNA was extracted from peripheral blood leucocytes
using Roche's DNA Isolation Kit for Mammalian Blood
(Roche Applied Science, Indianapolis, IN). DNA quantity
and quality were analyzed with a NanoDrop ND-100
spectrophotometer (NanoDrop Technologies LLC, Wilm-
ington, DE), Quant-iT™ PicoGreen® dsDNA Assay Kit (Inv-
itrogen Inc. Carlsbad, CA) and agarose gel electrophoresis.
High-quality DNA samples were diluted with PCR water
to a concentration of 10 ng/μl. Poor quality samples were
rescued by whole genome amplification with the REPLI-g®
Mini Kit from Qiagen (Valencia, CA). Samples that could
not be rescued were not used for HRM and do not appear
in Table 1.
HRM
Using Primer3 (frodo.wi.mit.edu), a pair of PCR primers
was designed to cover the entire TOR1A Exon 5 coding
sequence (forward: cagcaccttgtttcttcttcc, reverse: ccaactc-
caggcagtgactc). Another forward primer was synthesized
for site-directed mutagenesis of Exon 5 to generate the
c.863G>A mutation
(aacagcaccttgtttcttcttcccaggtggcttctggcacagcagcttaattgaccg-
gaacctcattgattattttgttcccttcctccccctggaatacaaacacctaaaaatgt
gtatccgagtggaaatgcagtcccAaggctatga). To evaluate HRM
results with amplicons of different sizes, a pair of previ-
ously-published primers was used to amplify the DYT1
ΔGAG region of Exon 5 [13].
The LightCycler® 480 Real-Time PCR system and High
Resolution Master Mix from Roche Applied Science (Indi-
anapolis, IN, USA) were used for HRM. The master mix
contains the LightCycler 480 ResoLight Dye. The High
Resolution Melting Master Mix is a ready-to-use hot-start
mix designed for PCR amplification followed by HRM
curve analysis for detection of sequence variants. Reso-
Light, a novel saturating DNA dye, was specifically
designed for detection of sequence variations by differ-
ences in melting curves. ResoLight can be used at high
concentrations without inhibiting PCR and its homoge-
neous staining of target sequences results in sharp melting
signals. As the temperature of the solution is increased
during HRM, the specific sequence of the amplicon (pri-
marily GC content and length) determines the melting
behavior. When the fluorescence signal is plotted against
temperature, fluorescence intensity decreases as double-
stranded DNA (dsDNA) becomes single stranded and
ResoLight is released. Since melting point (TM) differences
are often too small for reliable differentiation of ampli-
cons, separation is achieved by signal normalization and
temperature shifting (Fig 1a, c, e, and 1g). For normaliza-
tion, the pre- and post-melt signals are set to uniform rel-
ative values. For temperature shifting, the temperature
axes of the normalized melting curves are shifted to the
point where the entirety of dsDNA is denatured. The
LightCycler 480 Gene Scanning Software detects differ-
ences in melting curves and allocates samples to groups of
the same sequence. Finally, difference plots are created by
subtracting melting curves from a reference curve (Fig 1b,
d, f, and 1h).
The HRM Master Mix contains FastStart Taq DNA
polymerase, reaction buffer, a dNTP mix and ResoLight.
HRM was optimized to detect and differentiate the ΔGAG
and c.863G>A mutations by adjusting reaction conditions
and the concentrations of template DNA, primers and
MgCl2. To emulate the heterozygous state, a 1:1 mixture of
normal DNA with c.863G>A amplicons was utilized for
these reactions. Then, to define sensitivity and sensitivity,
HRM was performed with the collection of 96 samples
from Athena Diagnostics that included 8 samples with
confirmed DYT1 ΔGAG deletions and 88 additional sam-
ples with a clinical diagnosis of "dystonia." Optimized
reactions were performed in 96-well plates (Roche Cata-
log #04729692001) using 10–20 ng of template DNA, 1×
HRM Master Mix, 2.5 mM MgCl2 and 200 nM of each
primer in a 20-μl reaction volume. PCR cycling and HRM
conditions were carried out as follows: 95°C for 10 min;
45 cycles at 95°C for 10 s, 60°C for 15 s, and 72°C for 15
s; 95°C for 1 min, 40°C for 1 min, and the final HRM
temperature ramp from 70°C to 95°C rising at 0.1°C/s.
All subject samples and negative controls were run in
duplicate using 96-well plates.
With LightCycler 480 Gene Scanning Software, melting
curves and difference plots were analyzed by three investi-
gators (S.G., Y.Z., and M.S.L.) blinded to phenotype. All
samples were unambiguously assigned to one of three
genotypes (wild-type or normal, ΔGAG deletion, orBMC Medical Genetics 2009, 10:24 http://www.biomedcentral.com/1471-2350/10/24
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Table 1: Clinical diagnoses and demographics
Clinical diagnosis Number (age of 
onset)a
Family historyb Gender Race/Ethnicity TOR1A exon 5 
mutations
Male Female Non-Jewish
Caucasian
Jewish Other
Spasmodic dysphonia 422
(45.0 ± 15.7, 7–84)
7.3% 91 331 368 2 52 1 ΔGAG
Cervical dystonia 285
(43.7 ± 13.8, 4 – 76)
8.4% 71 214 268 1 16 0
Blepharospasm 67
(54.4 ± 10.1, 20–73)
10.4% 20 47 61 2 4 0
Writer's cramp 41
(35.3 ± 14.4, 7–60)
7.3% 17 24 35 0 6 0
Oromandibular 
dystonia
16
(48.9 ± 15.4, 20–70)
6.3% 3 13 13 1 2 0
Other primary focal 
dystonia
38
(37.8 ± 18.2, 10–74)
5.3% 14 24 34 0 4 0
Segmental dystonia 112
(48.7 ± 12.8, 14–74)
13.4% 39 73 101 0 11 0
Multifocal dystonia 16
(30.0 ± 15.9, 7–67)
25.0% 3 13 15 0 1 1 ΔGAG
Generalized dystonia 17
(18.2 ± 15.3, 1–57)
0.0% 7 10 17 0 0 0
Dystonia totals 1014
(44.3 ± 15.6, 1–84)
8.6% 265 749 912 6 96 2 GAG
Parkinson's disease 42
(63.0 ± 12.5, 28–82)
NA 19 23 39 0 3 0
Restless legs syndrome 31
(40.6 ± 18.3, 8–66)
NA 12 19 29 0 2 0
Essential tremor 14
(50.9 ± 15.4, 30–70)
NA 9 5 13 0 1 0
Other movement 
disorders
13
(49.8 ± 17.3, 27–71)
NA 9 4 12 0 1 0
Neurologically-normal 
controls
150
(56.5 ± 14.5, 23–83)c
NA 79 71 135 0 15 0
ΔGAG-negative 
dystonia
88
(NA)
NA NA NA NA NA NA 0
ΔGAG DYT1 dystonia 8
(NA)
NA NA NA NA NA NA 8 ΔGAG
Grand totals 1360 10 ΔGAG
aMean +/- standard error, range (yrs).
bFirst- or second-degree relative with dystonia.
cAge at study enrollment.
NA = not available or applicable.BMC Medical Genetics 2009, 10:24 http://www.biomedcentral.com/1471-2350/10/24
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c.863G>A mutation) by Gene Scanning Software. DNA
from wells with abnormal melting curves was purified
with the Qiagen QIAquick PCR Purification Kit. The
ΔGAG deletion and c.863G>A mutations were confirmed
by direct sequencing of purified PCR products in the for-
ward and reverse directions using an ABI Prism 377 DNA
Sequencer (Applied Biosystems, Foster City, CA, USA).
Results
HRM
As seen in Fig 1a and 1b, all 8 ΔGAG-positive samples
were clearly differentiated from the 88 ΔGAG-negative
samples; amplicons containing the ΔGAG mutation
melted/denatured prior to the ΔGAG-negative samples.
The  ΔGAG-positive samples clustered together on the
melting curves and difference plots with minimal sample-
to-sample variation. Furthermore, segregation of ΔGAG-
positive and ΔGAG-negative samples was maintained
despite 25-fold variation in the concentrations of DNA
templates from 0.1 ng/μl to 2.5 ng/μl (Fig 1c and 1d). No
false positive or false negative samples were detected
within this broad concentration range.
HRM robustly distinguished samples with either ΔGAG
deletions or c.863G>A mutations from normals (Fig 1e–
1h). Diagnostic sensitivity and diagnostic specificity for
ΔGAG deletion and c.863G>A mutation were 100% with
both primer pairs (Fig 1e–1h). As expected, the larger
TOR1A Exon 5 amplicon (314 bp, Fig 1e and 1f) had a
higher melting temperature (TM  = 83.2°C) than the
smaller amplicon (205 bp, TM = 81.2°C) which was gen-
erated with previously published primers [13].
LightCycler®  480 HRM Master Mix (Catalog
#04909631001) was purchased for $400 http://
www.roche-applied-science.com and contained reagents
for 500 reactions (20 μl reaction volume, $0.80/reaction).
LightCycler® 480 Multiwell Plates 96, white with sealing
foils (Catalog # 04729692001), must be used for HRM
and were purchased for $360/50 plates ($7.20/plate).
Excluding the costs of pipette tips and primers, 96 reac-
tions were completed for $84.00. On average, each plate
was setup, run, and analyzed in 3 hrs.
TOR1A Exon 5 Mutations in Non-Generalized Primary 
Dystonia
Two subjects (#1 and #2) with non-generalized primary
dystonia were found to harbor the classic DYT1 ΔGAG
deletion in Exon 5 of TOR1A. No TOR1A Exon 5 muta-
tions or variants were identified in the remaining 1012
subjects with dystonia or 250 controls. Subject #1 with the
classic DYT1 ΔGAG mutation exhibited multifocal dysto-
nia. She was a 48-yr-old non-Jewish Caucasian female
with cervical dystonia, spasmodic dysphonia (adductor
subtype), and writer's cramp. Cervical dystonia became
manifest at 12 yrs of age whereas laryngeal involvement
and writer's cramp became apparent at 39 and 45 yrs of
age, respectively. She reported consistent benefit from
injections of botulinum toxin type A for treatment of her
laryngeal and cervical dystonia. Her mother had never
been diagnosed with "dystonia" but reportedly exhibited
action-induced "leg tremors." A maternal aunt (her
mother's monozygotic twin) suffered from an undiag-
nosed voice disorder prior to her death. Subject #1 had
two siblings, both brothers. By report, one brother was
neurologically normal. The second brother developed
generalized dystonia at 9 years of age and died at 16 years
of age with respiratory complications.
Subject #2, also with the classic DYT1 ΔGAG mutation,
was a 63-yr-old woman of Ashkenazi Jewish descent. She
had spasmodic dysphonia (adductor subtype) that
became manifest at 19 years of age. Injections of botuli-
num toxin type A achieved consistently excellent results
over a period of 12 yrs. Subject #2 also exhibited a bilat-
eral upper extremity action tremor (<2 cm excursions).
She had one child who was neurologically normal. Her
mother and maternal grandmother had received diag-
noses of "essential tremor." None of her family members
were available for neurological examination.
Discussion
In 2000, Bressman and colleagues published diagnostic
testing guidelines for the DYT1 GAG deletion [25] and
recommended DYT1 ΔGAG testing in conjunction with
genetic counseling for subjects displaying primary dysto-
nia with onset prior to 26 yrs of age. Testing may be war-
ranted in subjects with onset after age 26 if they have an
affected relative with early-onset primary dystonia [25].
Our results are entirely consistent with those guidelines.
Although de novo ΔGAG mutations of TOR1A Exon 5 have
been described [26,27], our findings indicate that they
must be extraordinarily rare in non-generalized primary
dystonia in the United States. Furthermore, we have
shown that other TOR1A Exon 5 variants, including the
recently described c.863G>A missense mutation, must
also be rare in subjects with non-generalized primary dys-
tonia.
As outlined in Table 2, the classic DYT1 ΔGAG mutation
is uncommon in non-generalized primary dystonia and
quite rare in late-onset primary dystonia. The typical
DYT1 phenotype is characterized by early-onset in a limb,
most commonly a leg, with spread to other limbs and the
trunk over several years. Writer's cramp or more extensive
upper limb dystonia without task-specificity is the most
common presentation of adolescent- or late-onset pri-
mary dystonia due to the DYT1 ΔGAG mutation and most
of these subjects will have a positive family history of dys-
tonia [19]. However, DYT1 dystonia is phenotypicallyBMC Medical Genetics 2009, 10:24 http://www.biomedcentral.com/1471-2350/10/24
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HRM results of TOR1A Exon 5 coding region Figure 1
HRM results of TOR1A Exon 5 coding region. Normalized and temperature-shifted melting curves (a) and difference plots 
(b) for 8 ΔGAG-positive (red) and 88 ΔGAG-negative (blue) samples. Normalized and temperature-shifted melting curves (c) 
and difference plots (d) for one ΔGAG-positive (red) and five ΔGAG-negative (blue) samples with different concentrations of 
DNA template (0.1 ng/μl, 0.25 ng/μl, 0.5 ng/μl, 1 ng/μl, and 2.5 ng/μl; each in duplicate). Normalized and temperature-shifted 
melting curves (e) and difference plots (f) for ΔGAG-positive (green; one sample, in duplicate), ΔGAG-negative (red; three 
samples, each in duplicate) and c.863G>A mutation (blue; 1:1 mixtures of template DNA from normals with c.863G>A ampli-
cons) 314 bp amplicons. Normalized and temperature-shifted melting curves (g) and difference plots (h) for ΔGAG-positive 
(green; one sample, in duplicate), ΔGAG-negative (red; three samples, each in duplicate) and c.863G>A mutation (blue; 1:1 
mixtures of template DNA from normals with c.863G>A amplicons) 205 bp amplicons.BMC Medical Genetics 2009, 10:24 http://www.biomedcentral.com/1471-2350/10/24
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Table 2: DYT1 mutations in non-generalized primary dystonia
Reference Number of subjects with non-
generalized primary dystonia
Number with  GAG 
mutations
Phenotypic description of 
GAG-positive subjects
Valente et al. (1998) [15] 108 (Europe)
S = 48, F = 60
3 (2.8%) #1: S(arms), early-onset, FH+, Jewish
#2: F(arm), early-onset, FH-, Jewish
#3: F(arm), early-onset, FH+
Klein et al. (1999) [37] 300 
(United States, Germany, Italy; late-
onset & FH+)
S = 7, F = 293
3 (1.0%) #1: S(both legs & one arm), late-
onset, FH+
#2: F(cranial), late-onset, FH+
#3: F(NA), late-onset, FH+, Jewish
Brassat et al. (2000) [39] 90 (France, FH-)
S = 21, F = 69
1(1.1%) #1: S(leg & trunk), early-onset, FH-
Kamm et al. (2000) [40] 44 (Germany)
F = 44 (writer's cramp)
0 (0.0%) NA
Friedman et al. (2000) [41] 18 (United States)
F = 18 (musicians)
0 (0.0%) NA
Major et al. (2001) [42] 38 (Serbia)
M = 1, S = 22, F = 15
2 (5.3%) #1: S(both arms), early-onset, FH-
#2: M(right arm & left leg), early-
onset, FH-
Matsumoto et al. (2001) [43] 173 (Japan)
M = 4, S = 29, F = 144,
3 (1.7%) #1: F(arm), early-onset, FH+
#2: F(arm), early-onset, FH+
#3: F(leg), late-onset, FH+
Maniak et al. (2003) [8] 130 (Germany)
S = 10, F = 120
0 (0.0%) NA
Grundmann et al. (2003)[17] 244 (Germany)
M = 11, S = 46, F = 187
4 (1.6%) #1: M(both legs & right arm), early-
onset, FH-
#2: M(both arms & cranial), late-
onset, FH+
#3: S(both arms), early-onset, FH+
#4: S(both arms), early-onset, FH-
Kabakci et al. (2004) [18] 126 (Germany)
F + S = 126
0 (0%) NA
Im et al. (2004) [44] 155 (Korea)
S = 21, F = 134
2 (1.3%) #1: S(arm & shoulder), early-onset, 
FH+
#2: S(arm & neck), early-onset, FH-
Dhaenens et al. (2005) [45] 150 (France)
F = 150
1 (0.7%) #1: F(arm), onset?, FH+
Lin et al. (2006) [46] 186 (Taiwan)
M = 3, S = 47, F = 136
2 (1.1%) #1: F(leg), early-onset, FH+
#2: S(neck & trunk), late-onset, FH+
Jamora et al. (2006) [47] 54 (Singapore)
M = 1, S = 11, F = 41
0 (0.0%) NA
Naiya et al. (2006) [48] 150 (India)
F = 138, S = 12
0 (0%) NA
Gajos et al. (2007) [31] 48 (Poland)
G + S + F = 48
F = 2 (NA) #1: F(arm), late-onset, FH+
#2: F(arm), early-onset, FH+
G, generalized dystonia; M, multifocal dystonia; S, segmental dystonia; F, focal dystonia; FH, family history of dystonia; and NA, not applicable.BMC Medical Genetics 2009, 10:24 http://www.biomedcentral.com/1471-2350/10/24
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heterogeneous with oftentimes striking intrafamilial and
interfamilial variability [28-31]. Indeed, our subject #1
had childhood-onset cervical dystonia with much later
development of laryngeal dystonia and writer's cramp,
whereas subject #2 manifested dystonia with isolated
laryngeal involvement for over 40 yrs. Other remarkable
phenotypes described in the literature include onset of
focal dystonia at 64 yrs, status dystonicus, and late-onset
dystonia precipitated by exposure to a neuroleptic
[29,30].
In comparison with several of the studies listed in Table 2,
the percentage of ΔGAG mutations was relatively low in
our cohort of subjects with non-generalized dystonia.
Approximately, 90% of our patients with primary dysto-
nia were non-Jewish Caucasians born in the United States;
only 6 Jewish subjects were screened for TOR1A Exon 5
mutations. Since the carrier frequency of the classic DYT1
ΔGAG mutation is estimated at 1:1000–1:3000 in
Ashkenazi Jews [32] and less than 1:30,000 in non-Jews
[33], inclusion of additional Jewish subjects may have
increased our percentage of ΔGAG cases.
Our study was limited to interrogation of Exon 5 of
TOR1A and does not exclude a role for TOR1A mutations
and/or variants in the etiopathogenesis of late-onset pri-
mary dystonia. Single nucleotide polymorphisms (SNPs)
within or in close proximity to the 3' UTR of TOR1A may
be associated with primary focal dystonia [34-36]. Muta-
tions in Exons 1–4 and associations between dystonia
phenotypes and TOR1A copy number variants and single
nucleotide polymorphisms must be interrogated in future
studies.
Previous studies of primary dystonia have employed a
wide variety of methods for detection of TOR1A muta-
tions [13,21,37-49]. For large cohorts, direct sequencing
of each sample is expensive, labor intensive, and ineffi-
cient. Similarly, previously employed techniques such as
PCR-based polyacrylamide gel electrophoresis (PAGE)
with silver staining [37], restriction fragment length poly-
morphism (RFLP) analysis with restriction enzyme BseR1
[38-48] and SSCP (single-strand conformation polymor-
phism) analysis [13,21], are slow, requiring multiple steps
including gel electrophoresis. Although not gel-depend-
ent, denaturing high-performance liquid chromatography
(DHPLC) also requires post-PCR handling which is labor-
intensive and associated with the risk of well-to-well cross
contamination [49].
HRM has recently been introduced as a screening method
for mutation detection. HRM is a closed-tube method that
can be performed in a rapid, economical, reliable, and
high-throughput fashion. In a comparative study, Chou
and colleagues showed that HRM is superior to DHPLC
[50]. HRM has been utilized for the detection of germline
and somatic mutations as well as SNP genotyping with
high sensitivity and specificity [23,51-54]. Other HRM
applications include microsatellite analysis, screening for
loss of heterozygosity, and DNA methylation analysis.
The utility and efficiency of HRM can be maximized by
careful experimental design. In our study, a single pair of
primers was designed to cover the entire coding region of
TOR1A Exon 5 and generated a 314 bp amplicon. Theo-
retically, differentiation of samples carrying a sequence
variation is better with shorter amplicons. In general,
amplicons from 50 to 250 bp are ideal for HRM, particu-
larly when employed for SNP and homozygous mutation
analysis. However, 100% sensitivity and specificity has
been observed with amplicons larger than 600 bp [55].
Thus, the clear separation of 314 bp amplicons harboring
heterozygous  ΔGAG and c.863G>A mutations was not
unexpected.
HRM offers additional advantages over older screening
techniques. First, amplicons of interest only require puri-
fication prior to follow-up sequencing. There is no need to
PCR amplify DNA templates. Second, HRM robustly dif-
ferentiates genotypes despite moderate differences in
well-to-well concentrations of DNA templates. Lastly,
Roche's LightCycler® 480 Real-Time PCR system offers
384-well plate capabilities which, when coupled with a
robotic workstation, permits completion of very large
projects (>10,000 samples) in a single week. Clearly,
HRM is well-suited for many candidate gene and SNP-
association studies of dystonia and other neurological dis-
orders.
Conclusion
In conclusion, we have developed a fast, efficient and reli-
able screening method for known mutations (ΔGAG and
c.863G>A) within the coding region of TOR1A Exon 5
using HRM. HRM showed 100% diagnostic sensitivity
and specificity. In a large cohort of patients with non-gen-
eralized primary dystonia in the US, TOR1A Exon 5 muta-
tions were very uncommon; only two classic DYT1 ΔGAG
and no c.863G>A mutations were identified. HRM may be
applicable to high-throughput mutation detection in
other movement and general neurological disorders.
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